Ascendis Pharma A/S (NASDAQ:ASND) Sees Significant Decrease in Short Interest

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 3,420,000 shares, a drop of 5.5% from the December 15th total of 3,620,000 shares. Based on an average daily volume of 426,500 shares, the days-to-cover ratio is currently 8.0 days.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors have recently bought and sold shares of the company. Westfield Capital Management Co. LP grew its holdings in shares of Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares during the period. Janus Henderson Group PLC grew its stake in Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after buying an additional 155,971 shares during the last quarter. Finally, Groupama Asset Managment bought a new stake in Ascendis Pharma A/S during the third quarter worth $60,000.

Ascendis Pharma A/S Trading Down 2.7 %

Ascendis Pharma A/S stock opened at $128.13 on Friday. The business has a 50-day moving average of $133.13 and a 200-day moving average of $133.48. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The firm has a market capitalization of $7.78 billion, a P/E ratio of -15.86 and a beta of 0.65.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ASND shares. Oppenheimer cut their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. TD Cowen reduced their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $192.07.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.